Here's a commentary on the EU Parliament's current efforts to ban compensation to plasma donors in the EU, published today.
Julio J Elias, Nicola Lacetera, Mario Macis, Axel Ockenfels, Alvin E Roth, "Quality and safety for substances of human origins: scientific evidence and the new EU regulations," BMJ Global Health, Volume 9, Issue 4 (21 April, 2024) https://doi.org/10.1136/bmjgh-2024-015122
"Summary box
The new European Union (EU) ‘Regulation on standards of quality and safety for substances of human origin (SoHOs) intended for human application’ is based on a long-standing diffidence towards offering compensation to donors of SoHOs.
We point to recent, growing empirical evidence indicating that carefully designed compensation can increase the supply of SoHOs without negatively affecting quality and safety. We also elaborate arguments that address some of the moral concerns that motivate the aversion to payments.
As member states proceed to adopt the new EU regulation, our article may provide insights on how to achieve both self-sufficiency and safety"
...
"At least where plasma for fractionation is concerned, the unpaid-donor system has failed to meet demand. Table 1 indicates that in Europe, countries allowing monetary compensation for donors are the only ones achieving self-sufficiency in plasma collection for the production of immunoglobulin. The plasma sector in countries that compensate plasma donors, notably the USA, serves as supplier to many countries experiencing chronic shortages. The USA alone collects about 70% of the world’s plasma supply.10 A combination of a favourable regulatory environment, an extensive collection network and advanced technological infrastructure contributed to establishing the US position.11
Country | Reliance on domestic supply (% of total national need) | Monetary payments allowed | Current payment amount | Other incentives |
Austria (2020) | 100 | Yes | €30–40 | – |
Czech Republic (2020) | 100 | Yes | €30–35 | – |
Germany (2020) | 100 | Yes | €25 | – |
Hungary (2020) | 100 | Yes | €30 | – |
Latvia (2018) | 100 | Yes | €17 | – |
Italy (2018) | 76 | No | – | Paid leave of absence from work |
Slovenia (2017) | 54 | No | – | Paid leave of absence from work |
Belgium (2019) | 50 | No | – | Paid leave of absence from work |
France (2020) | 50 | No | – | – |
Netherlands (2020) | 45 | No | – | – |
Slovakia (2018) | 41 | No | – | – |
Denmark (2018) | 34 | No | – | – |
Spain (2020) | 34 | No | – | – |
Portugal (2018) | 22 | No | – | Exemption from National Health Service user fees |
The table shows, for each country, the percentage of plasma needed for immunoglobulin (Ig) production that is collected domestically. The year in parenthesis is the one to which the data on self-reliance refer. The table then reports whether monetary payments are allowed, the current range of payments per donation and any other incentives in use in each country. In countries that allow payments, plasma collectors offer, in addition to monetary compensation for each donation, additional monetary or in-kind rewards, for example, when a donor reaches a certain number of donations (eg, 5, 10,…), or to first-time donors. The figures reported above do not include these additional rewards.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.